Benitec Biopharma
Update in progressBNTC (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines. Its Silence and Replace platform combines RNA interference with gene therapy to achieve sustained silencing of disease-causing genes along with delivery of wild-type replacement genes in a single administration. The lead program, BB-301, is an AAV-based therapy intended to treat dysphagia in oculopharyngeal muscular dystrophy by silencing the disease gene. Headquartered in Hayward, California.
Company score
- Sentiment
- -0.03
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.11
- Governance
- 0.03
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.00
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Jerel A. Banks M.D., Ph.D.
- Employees19
- Websitebenitec.com
Identifiers
- ISINUS08205P2092
- FIGIBBG00R712L56
- CUSIP082053208
- CIK0001808898